The Hippo

HOME| ADVERTISING | CONTACT US|

Warfarin and Risk of Bleeding Concord NH

Warfarin is effective in preventing blood clots that can cause stroke in patients with atrial fibrillation (abnormal heart rhythm) and other diseases, but the drug has a narrow therapeutic range in which it prevents strokes but doesn't cause bleeding, according to the researchers. This means that effective warfarin treatment requires regular laboratory monitoring to ensure warfarin levels remain in the range that lowers the risk of stroke without increasing the risk of bleeding.

Hoke H Shirley III, MD
(603) 224-3368
264 Pleasant St
Concord, NH
Business
Concord Orthopaedic Professional Associates
Specialties
Rheumatology

Data Provided by:
Lake Side Animal Hospital
(603) 524-2553
552 Laconia Road
Tilton, NH

Data Provided by:
Andrew M Jaffee
(603) 227-7000
250 Pleasant St
Concord, NH
Specialty
Internal Medicine, Emergency Medicine

Data Provided by:
Andrew Lex Taylor
(603) 229-5230
253 Pleasant St
Concord, NH
Specialty
Internal Medicine, Endocrinology, Diabetes & Metabolism

Data Provided by:
Francis R Hayes
(603) 228-0071
250 Pleasant St
Concord, NH
Specialty
Family Practice

Data Provided by:
Clifford M Levy, MD
(603) 224-3368
264 Pleasant St
Concord, NH
Business
Concord Orthopaedic Professional Associates
Specialties
Orthopedics

Data Provided by:
Northside Animal Hospital
(603) 622-5299
574 Arah Street
Hooksett, NH

Data Provided by:
Alexander Gadbois
(603) 227-7000
250 Pleasant St
Concord, NH
Specialty
Internal Medicine

Data Provided by:
Karen M Bryant
(603) 227-7000
250 Pleasant St
Concord, NH
Specialty
Internal Medicine, Geriatric Medicine

Data Provided by:
Cooper Brian Stacey
(603) 229-5200
253 Pleasant St
Concord, NH
Specialty
Family Practice

Data Provided by:
Data Provided by:

Warfarin and Risk of Bleeding

Provided By:

SUNDAY, Nov. 15 (HealthDay News) -- The anti-clotting drug dabigatran etexilate (Pradaxa) may be more effective and safer than warfarin at preventing clots and stroke in patients with atrial fibrillation, a new Swedish study has found.

Warfarin is effective in preventing blood clots that can cause stroke in patients with atrial fibrillation (abnormal heart rhythm) and other diseases, but the drug has a narrow therapeutic range in which it prevents strokes but doesn't cause bleeding, according to the researchers. This means that effective warfarin treatment requires regular laboratory monitoring to ensure warfarin levels remain in the range that lowers the risk of stroke without increasing the risk of bleeding.

This study included 18,113 atrial fibrillation patients in 44 countries who were randomly selected to receive either oral treatment with standard warfarin (6,022 patients) or dabigatran etexilate at either 110 milligrams (6,015 patients) or 150 milligrams (6,076 patients).

After one to three years of follow-up, 1.69 percent of patients in the warfarin group suffered a stroke or serious clot per year, compared with 1.53 percent and 1.11 percent of patients taking 110-milligram and 150-milligram doses of dabigatran etexilate, respectively, the study authors, from University Hospital in Uppsala, found.

Rates per year of major bleeding were 3.36 percent in the warfarin group and 2.71 percent and 3.11 percent for patients taking 110-milligram and 150-milligram doses of dabigatran etexilate, respectively.

The study was scheduled to be presented Sunday at the American Heart Association's annual meeting in Orlando, Fla.

The patients in the study were an average age of 72 and included some who'd suffered a prior stroke (13 percent), patients with high blood pressure (79 percent), those who'd never taken an oral anti-clotting drug for more than two months (50.4 percent), and those who weren't using an oral anti-clotting drug when they enrolled in the study (34 percent).

Dabigatran etexilate is approved for use in Canada and Europe but not in the United States.

More information

The American Academy of Family Physicians has more about atrial fibrillation.

SOURCE: American Heart Association, news release, Nov. 15, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

®2010 Hippo Press. site by wedu